Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Cap Nazla: Two capsules twice daily orally to be taken wit water for 7 days
Control Intervention1: Tab Levocetirizine: One tablet of 5 mg once daily orally to be taken with water for 7
Sponsors
Central Council for Research in Unani Medicine (CCRUM), New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex in the age group of 18-65 2. Patients of Nazla Haar presenting the following sign and symptoms: Nasal irritation/ Nasal Itching Redness of Face Redness of Eyes Discharge of yellowish secretion of thin consistency
Exclusion criteria
Exclusion criteria: 1. Known cases of Acute or Chronic lower respiratory tract infection like pneumonia, Bronchitis, Asthma and Bronchiectasis. 2. Fever > 100oF. 3. Known cases of any other acute illness. 4. Known cases of long standing chronic illnesses. 5. Pregnant and lactating women. 6. History of Addiction (smoking, alcohol) 7. History of hepatic, renal disorders, Diabetes Mellitus, Hypertension, or any other ailment needing long term therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in sign and symptoms of Nazla Haar(Common cold/Allergic Rhinitis)Timepoint: On baseline, 3rd day and 7th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical assessment for safety assessmentTimepoint: On baseline and at the end of treatment | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine (CCRUM)
Outcome results
None listed